# Diabetes Research Hub — Monitor Review

**Run date:** 2026-08-14 (automated, unattended)
**Scope:** Read-only review of latest script outputs. No files modified.

---

## Headline: data-collection pipeline still stalled — now 28 days frozen

The most actionable finding is unchanged from yesterday's run and getting worse with age. The two baseline collectors (`baseline_clinical_trials.py`, `baseline_pubmed_alerts.py`) and the file monitor (`hub_monitor.py`) have produced no new output since **2026-07-17**. Everything in the trial/PubMed sections below is a re-review of that frozen snapshot, not new intelligence.

| File | Last updated | Age | Status |
|------|-------------|-----|--------|
| `clinical_trials_latest.json` | 2026-07-17 | 28 days | **STALE** |
| `pubmed_recent_latest.json` | 2026-07-17 | 28 days | **STALE** |
| `hub_monitor_report.md` | 2026-07-17 | 28 days | **STALE** |
| `literature_gap_data.json` | 2026-07-18 | 27 days | **STALE** |
| `literature_gap_report.md` | 2026-08-13 | 1 day | Fresh (re-rendered on old data) |
| `agent_state.json` | 2026-08-13 | 1 day | Fresh |
| Latest trial/PubMed snapshot | `*_2026-07-17.json` | 28 days | **STALE** |

**Interpretation [Certain on staleness; Likely on cause]:** The daily agent loop, gap analysis, and citation steps are still firing (`agent_state.json` and `literature_gap_report.md` are current). But the *data-ingestion half* of the pipeline — the two collectors plus `hub_monitor.py` — has been dark for four weeks. The nightly snapshot series also ends 2026-07-17. Note the gap report re-rendered on 2026-08-13 still carries a date range ending `2026/07/17`, confirming it is recomputing over frozen input. This is the second consecutive run flagging the same break; it did not self-heal overnight.

> ⚠️ Trial and PubMed findings below reflect **2026-07-17**, not today. Treat as re-review of the last live snapshot.

---

## File System Status

- 459 files in `Analysis/Results`. `hub_monitor.py`'s own last review flagged **827 result files older than 14 days**.
- Backups healthy: `agent_state.json.bak_*` series continues daily through mid-August.
- No new snapshot files created since 2026-07-17 — confirms collectors remain down.
- Missing expected fresh files: none newly missing; the issue is stale, not deleted.

## Clinical Trial Changes

No new live data since last run. Below is the last live window (2026-06-17 → 2026-07-17), unchanged from yesterday and repeated only for continuity.

**Totals at 2026-07-17:** 858 tracked trials (+62 / −17 vs. one month prior). Categories: T1D Cure & Cell Therapy 152, T1D Immunotherapy & Prevention 76, T2D Novel Therapies 147, Diabetes Technology 236, Recently Completed w/ Results 321. **52 Phase 3 trials are in RECRUITING status.**

**Key Phase 3 trials — priority organizations (status as of 2026-07-17):**

| NCT | Sponsor | Therapy | Status |
|-----|---------|---------|--------|
| NCT04786262 | Vertex | VX-880 (zimislecel), T1D | RECRUITING |
| NCT06832410 | Vertex | VX-880 in T1D + kidney transplant | RECRUITING |
| NCT07222332 | Eli Lilly | Baricitinib — preserve beta-cell (BARICADE-PRESERVE) | RECRUITING |
| NCT07222137 | Eli Lilly | Baricitinib — delay Stage 3 T1D | RECRUITING |
| NCT07088068 | Sanofi | Teplizumab vs placebo, Stage 3 T1D (ages 1–25) | RECRUITING |
| NCT07076199 | Novo Nordisk | Insulin icodec (weekly) in T1D | RECRUITING |
| NCT07564414 | Novo Nordisk | CagriSema, obesity ± T2D | RECRUITING |
| NCT06260722 | Eli Lilly | Retatrutide vs semaglutide, T2D (TRANSCEND-T2D-2) | ACTIVE, NOT RECRUITING |

**Recently posted results worth reviewing (from frozen snapshot, latest first):**
- NCT05086445 — Lilly, orforglipron (LY3502970) in Japanese T2D — results 2026-07-16
- NCT04255433 — Lilly, tirzepatide vs dulaglutide MACE outcomes, T2D — results 2026-07-13
- NCT05254002 — Bayer, finerenone + empagliflozin in CKD/T2D — results 2026-07-13
- NCT06010004 — Lilly, long-term safety of orforglipron in T2D — results 2026-06-30

## PubMed Highlights

From `pubmed_recent_latest.json` (generated 2026-07-17, 30-day lookback, 158 unique papers). **All 16 domain_results buckets show 0** in the latest file — consistent with a truncated/failed final collector run, another symptom of the stall.

**Cross-domain papers (highest value — appear in ≥2 alert domains):**
- [42459945] "Algorithmic discrimination risks in training data: pediatric T1D case" — Diabetes AI/ML × Closed Loop AP × Health Equity (triple-domain; aligns with Tier 1 #6 Epidemiology/Equity)
- [42458355] "Socioeconomic gradients in hypertension prevalence and management" — AI/ML × Health Equity
- [42419792] "Comparative effects of drugs for overweight/obesity: systematic review" — orforglipron × retatrutide × CagriSema
- [42453334] "Noncoding RNAs for diabetes research and therapy" — Biomarker × LADA
- [42459212] / [42458730] Precision-nutrition / multi-omic BMI modelling — Microbiome × Multi-Omics (aligns with Tier 1 #1 Multi-Omics)

**Key-therapy mentions (paper counts):** orforglipron 5, CagriSema 5, dapagliflozin 5, retatrutide 4, teplizumab 4, icodec 3, baricitinib 2. **zimislecel: 0** — no PubMed hits in the window despite active Phase 3.

## Gap Analysis Summary — Top 5 under-researched intersections

From `literature_gap_data.json` (`ranked_gaps`, all `reliable: true`, Gap Score 100, zero joint publications). **Validation level: BRONZE** — single analytic source, needs expert confirmation per Research Doctrine.

| Rank | Domain 1 × Domain 2 | Joint pubs | Note |
|------|---------------------|-----------|------|
| 1 | GWAS/Polygenic × Closed Loop/AP | 0 | Likely methodologically distinct (genomics vs. device eng) |
| 2 | Drug Repurposing × CGM Technology | 0 | Likely methodologically distinct |
| 3 | Treg/CAR-T × Neuropathy | 0 | **Meaningful gap** — immune-mediated neuropathy + Treg modulation |
| 4 | Beta Cell Regen × Health Equity | 0 | **Meaningful gap** — access to emerging cell therapies |
| 5 | Treg/CAR-T × Health Equity | 0 | **Meaningful gap** — equity of advanced immunotherapies |

**Tier 1 alignment:** Ranks 4 and 5 map to Tier 1 #6 (Epidemiological/Health-Equity analysis) — data is public (GBD, CDC, IDF) and the gap is a legitimate synthesis target. Rank 3 maps to Tier 2 immunotherapy synthesis. The gap report's own top curated "meaningful" list also elevates *Beta Cell Regen × Health Equity* and *Gene Therapy × LADA* — both viable literature-synthesis starts.

## Breaking News (web check, last 7 days)

Nothing genuinely new in the trailing 7 days. Significant items are all pre-existing and already tracked:

- **Orforglipron (Foundayo, Lilly)** — FDA-approved **2026-04-01** for chronic weight management (oral GLP-1). The **T2D indication was submitted to FDA in Q2 2026 and remains pending** — worth watching for an approval decision. [Likely]
- **Zimislecel (VX-880, Vertex)** — still investigational; global regulatory submissions expected during 2026, realistic approval 2027–2028. No approval event. [Likely]
- No FDA diabetes approvals or major Phase 3 readouts dated 2026-08-07 through 2026-08-14 surfaced.

## Recommended Actions

1. **Fix the ingestion break (highest priority — 28 days stale).** Re-run the three dark scripts and confirm they write fresh output:
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   - `python hub_monitor.py`
   Then check for a `clinical_trials_snapshot_2026-08-14.json` and `pubmed_recent_snapshot_2026-08-14.json`. If they still fail, inspect the collector logs / API credentials — the daily agent loop kept running, so this is isolated to the ingestion scripts.
2. **Re-run gap analysis after data refresh.** `literature_gap_data.json` is 27 days old; the Aug-13 report is a re-render over frozen input, so its "freshness" is misleading. Run `python project1_literature_gap_analysis.py` once new PubMed data lands.
3. **Track pending FDA decision on orforglipron for T2D** (Lilly Q2-2026 submission). If approved, update the tracker and the T2D Novel Therapies category.
4. **Verify the two meaningful, Tier-1-aligned gaps** before acting: *Beta Cell Regen × Health Equity* and *Treg/CAR-T × Health Equity*. Cross-check against Cochrane/PROSPERO to confirm no existing review covers the intersection (per Doctrine). Both remain BRONZE until expert-confirmed.
5. **Manually verify zimislecel/VX-880 Phase 3 status** (NCT04786262, NCT06832410) at next live refresh — 0 PubMed hits despite active trials suggests the snapshot may be undercounting this program.

---

*Generated by Diabetes Research Hub automated monitor — 2026-08-14. Read-only run; no source files modified. Evidence levels noted inline per Research Doctrine v1.0.*
